Interferon Testing

Comprehensive Interferon Testing: Ultrasensitive Multiplex Immunoassay, Functional Bioactivity, and Gene Expression Profiling for Immunology and Infectious Disease Management

Interferons (IFNs) are a family of pleiotropic cytokines that constitute a first line of defence against viral infections, modulate antitumour immunity, and regulate autoimmune and inflammatory responses. The three major classes—type I (IFN‑α, IFN‑β, and their subtypes), type II (IFN‑γ), and type III (IFN‑λ)—exert distinct but overlapping biological effects through specific receptor complexes and downstream JAK‑STAT signalling pathways. Clinicians and researchers seek interferon testing not only to quantify circulating or local cytokine levels but also to assess functional bioactivity, distinguish between subtypes, monitor therapeutic responses to IFN‑based therapies, and evaluate innate and adaptive immune competence in patients with chronic infections, autoimmune disorders, or primary immunodeficiencies. Our laboratory offers a comprehensive, multi‑dimensional interferon testing service that integrates high‑sensitivity multiplex chemiluminescent immunoassays, cell‑based functional bioassays, and quantitative RT‑PCR for IFN‑stimulated gene (ISG) expression, delivering an unparalleled analytical and biological insight for precision immunodiagnostics.

The Clinical Rationale for Integrated Interferon Profiling

Conventional interferon measurement by single‑plex ELISA or electrochemiluminescence provides total protein concentration but fails to distinguish between the different subtypes (e.g., IFN‑α2a vs. IFN‑α2b), nor does it evaluate the biological activity of the cytokine, which can be affected by post‑translational modifications, aggregation, and the presence of natural antagonists such as autoantibodies or soluble receptors. Moreover, circulating interferon levels are often low or undetectable in many chronic conditions, yet tissue‑specific or cell‑associated interferon responses may be highly relevant. Our core interferon panel includes quantitative measurement of IFN‑α (pan‑α and specific subtypes), IFN‑β, IFN‑γ, and IFN‑λ (IFN‑λ1/IL‑29, IFN‑λ2/IL‑28A, IFN‑λ3/IL‑28B) using highly specific monoclonal antibody‑based chemiluminescence assays with limits of quantification (LOQs) in the low pg/mL range. These are complemented by a functional interferon bioassay using a validated reporter cell line (e.g., A549‑ISRE‑luciferase or HEK‑Blue™ IFN‑α/β cells) that measures the ability of patient samples to induce interferon‑stimulated response element (ISRE)‑driven luciferase expression, reflecting the total bioactivity of all type I IFNs and type III IFNs present. For IFN‑γ, we use a separate reporter system (e.g., THP‑1‑GAS‑luciferase) to specifically quantify its functional activity. This dual‑bioassay approach provides a direct measure of the net signalling capacity of the patient's endogenous interferons, which is not captured by immunoassays alone.

For patients on interferon‑based therapies (e.g., pegylated IFN‑α for hepatitis C or IFN‑β for multiple sclerosis), we offer therapeutic drug monitoring including trough drug levels, neutralising anti‑interferon antibodies (NAbs), and a functional neutralisation assay that measures the residual antiviral activity of patient serum. In addition, we provide quantitative RT‑PCR profiling of a panel of interferon‑stimulated genes (ISGs) (e.g., MX1, OAS1, ISG15, IFIT1, RSAD2) in whole blood or isolated PBMCs, which serves as a highly sensitive and integrated biomarker of the endogenous interferon signature—a parameter increasingly used to classify autoimmune diseases (e.g., lupus, dermatomyositis) and to predict responses to immunomodulatory agents.

Our Analytical Capabilities: Sensitivity, Specificity, and Subtype Discrimination

Our primary immunoassay platform is a fully automated, paramagnetic bead‑based multiplex chemiluminescent system capable of simultaneously quantifying up to 10 interferon‑related analytes in a single 50‑µL sample, with LOQs of 0.2–1.0 pg/mL depending on the analyte. These assays employ highly validated monoclonal antibodies with demonstrated minimal cross‑reactivity to other cytokines and to homologous interferon subtypes (e.g., <0.5% cross‑reactivity between IFN‑α subtypes). For IFN‑γ, we offer both total IFN‑γ and its bioactive dimeric form, using a conformation‑specific antibody pair that selectively recognises the homodimer. Our functional bioassays are performed in a GLP‑compliant cell culture laboratory using cryopreserved, quality‑controlled reporter cells. The type I/III bioassay can detect as low as 0.5 IU/mL (referenced to the WHO international standard for IFN‑α), with inter‑assay CV < 10%. The IFN‑γ bioassay achieves an LOQ of 0.1 IU/mL and is run concurrently with a neutralisation control to confirm specificity. We also provide a subtype‑specific bioassay for IFN‑α2 using a monoclonal antibody neutralisation step, enabling the differentiation of IFN‑α2 from other type I IFNs.

Our ISG expression profiling employs a validated TaqMan™ array with custom primer‑probe sets for 17 ISGs and 3 housekeeping genes, performed on a high‑throughput real‑time PCR platform with built‑in quality controls for RNA integrity and reverse transcription efficiency. Results are reported as fold‑change relative to a healthy control pool, and we provide a composite “interferon score” (averaging the log2‑transformed expression of a subset of robust ISGs) that has been clinically validated to correlate with disease activity in systemic lupus erythematosus and dermatomyositis. This ISG signature is particularly valuable when protein levels are undetectable but a functional interferon response is still present.

Regulatory Compliance and Quality Assurance

All interferon testing services are conducted under CLIA '88 and CAP accreditation, with immunoassays validated according to CLSI EP‑A2, EP‑A5, and EP‑A7 guidelines. Our cell‑based bioassays are performed under strict aseptic conditions with comprehensive quality controls, including a reference standard curve (WHO international standard), a positive control (recombinant IFN), a negative control (healthy donor serum), and a matrix interference control. We participate in external proficiency testing for cytokine assays and for bioactivity measurements, as available, and we maintain stringent documentation for all procedures. Each report provides both the immunoassay concentration and the bioactivity value, along with a bioactivity‑to‑immunoreactivity ratio that helps identify samples with functional inhibitors (e.g., autoantibodies or soluble receptors). For ISG profiles, we include a quality‑control flag for RNA integrity and a heatmap visualisation of the gene expression pattern, along with the interferon score and its percentile rank relative to our disease‑specific reference database.

Our Distinctive Advantages in Interferon Testing

Our laboratory offers several unique benefits that directly address the limitations of conventional interferon testing. First, we provide a truly integrated service—combining protein concentration, functional activity, and ISG expression—within a single comprehensive report, enabling a holistic view of the interferon system from the molecular to the functional level. Second, our multiplex chemiluminescence platform allows simultaneous quantification of all major interferon classes and their subtypes, which is essential for characterising the specific interferon signature in autoimmune diseases (e.g., lupus is often IFN‑α‑driven, while dermatomyositis shows IFN‑β predominance). Third, our functional bioassays are not simply surrogate markers; they directly measure the signalling capacity of the patient's endogenous interferons, accounting for complexation, post‑translational modifications, and receptor‑binding efficiency. We have demonstrated that the bioactivity‑to‑immunoreactivity ratio can differentiate between active disease and quiescent states, even when absolute protein levels are within the normal range.

Fourth, our ISG expression profiling is performed using a whole‑blood PAXgene™ system that stabilises RNA immediately, allowing for convenient home or clinic collection and shipment without the need for immediate PBMC isolation. Our ISG score has been shown to correlate with clinical flare risk in lupus and to predict response to JAK inhibitors. Fifth, we offer serial monitoring packages that include trending of both protein bioactivity and ISG scores, with automated alerts for significant changes (e.g., a >2‑fold increase in bioactivity or a >1.5‑fold increase in ISG score) that may precede clinical exacerbations. Our expert immunology team provides interpretive consultations, integrating the interferon profile with other cytokine panels (e.g., TNF, IL‑6, IL‑10) and clinical data to guide therapeutic decisions.

Specimen Types and Clinical Applications

Our interferon testing is validated on serum, plasma (EDTA, heparin), and, for ISG profiling, on whole blood collected in PAXgene RNA tubes (or Tempus tubes). We also offer stimulated interferon assays using whole blood or PBMC cultures with mitogens (e.g., PHA, LPS) or specific antigens (e.g., CMV, EBV) to assess cellular immune function, particularly for primary immunodeficiencies and chronic infections. Clinical applications span the diagnosis and monitoring of autoimmune diseases (SLE, Sjögren’s, myositis), the evaluation of viral infections (HIV, HCV, HBV, COVID‑19), the assessment of interferonopathies (e.g., Aicardi‑Goutières syndrome), therapeutic monitoring of interferon‑based drugs, and the prediction of immunotoxicity during cancer immunotherapy. In the post‑COVID context, our integrated interferon panel has proven valuable in characterising post‑viral fatigue syndromes and in assessing the risk of severe disease.

Innovation and Research Collaborations

We are at the forefront of developing single‑cell interferon secretion assays using droplet microfluidics and digital ELISA for ultra‑sensitive detection of low‑abundance interferon subtypes. Our research team is also validating a novel interferon‑induced protein (IP‑10/CXCL10) ratio as a surrogate for tissue interferon activity. We actively collaborate with academic centres to establish population‑specific reference intervals and to investigate the role of interferon in emerging diseases. Our contributions to standardisation efforts, including the development of the International Interferon Bioactivity Reference Panel, ensure that our testing services remain evidence‑based and internationally comparable.

Client Support and Service Model

We provide comprehensive support from test ordering to result delivery. For ISG profiling, we supply PAXgene collection kits with pre‑paid shipping to ensure RNA stability. Our standard turnaround time is 24‑48 hours for immunoassays, 48‑72 hours for functional bioassays, and 72 hours for complete integrated reports (including ISG profiling). STAT and urgent options are available. All results are delivered via a secure electronic portal with interactive graphs and trend visualisation. We offer volume‑based pricing, free courier collection, and dedicated account management for research studies and high‑volume clinical centres. We also provide educational materials and case‑based webinars to help clinicians interpret complex interferon profiles and incorporate them into practice.

Conclusion: Interferon Testing as a Multi‑Layered Immune Function Biomarker

Interferon testing, when performed with subtype resolution, functional bioactivity measurement, and downstream gene‑expression analysis, evolves from a simple cytokine measurement into a comprehensive assessment of the innate immune system's activation state. Our laboratory delivers this integrated solution—combining high‑sensitivity multiplex immunoassay, cell‑based functional bioassays, ISG expression profiling, and expert clinical interpretation—to empower clinicians with actionable insights for the management of autoimmune, infectious, and neoplastic diseases. Whether the clinical question involves characterising an interferon‑driven autoimmune endotype, monitoring response to antiviral therapy, or assessing immune competence, our services provide the accuracy, depth, and translational relevance essential for optimal patient care.

We invite you to partner with us for your interferon testing needs. Our dedicated immunology team is ready to assist with test selection, protocol customisation, and result interpretation, ensuring you receive not only reliable laboratory data but also a strategic framework for integrating interferon biomarkers into clinical decision‑making. Choose our laboratory for excellence in cytokine and immune function analysis, supported by scientific rigour, technological innovation, and an unwavering commitment to quality.